23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Merkel Cell Carcinoma.
Blockbuster deals are shaping key player CMOs despite 31% drop in M&A
Despite a difficult investing environment, major well-capitalised contract manufacturing organisations (CMOs) have been involved in recent acquisitions, as big pharma and private equity alike highly value